プラズマエキスパンダ市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、エンドユーザー別、地域別、競合別、2020～2030年

プラズマエキスパンダの世界市場規模は、2024年に73億2,000万米ドルとなり、2030年には150億3,000万米ドルに成長すると予測され、CAGRは12.71%です。

この市場は、外傷、外科手術、熱傷、ショックなどの重篤な状態における容積補充に対するヘルスケア需要の増加を背景に、大きく拡大する見通しです。血漿増量剤は重要な静脈注射液であり、血液量の回復に役立ち、重度の脱水や失血の治療に不可欠です。さらに、心不全、肝疾患、腎障害などの慢性疾患の有病率の増加は、これらの製品に対する需要をさらに加速させています。重篤な患者の体液バランスの管理と心血管の健康維持に重要な役割を果たすからです。手術や集中的な医療処置の頻度が増加していることも、市場の成長に拍車をかけています。

プラズマエキスパンダ市場の急速な成長にはいくつかの要因が寄与しています。ヒドロキシエチルデンプン（HES）やその他の合成コロイドなどの合成血漿拡張剤の採用が増加していることが、ヒトアルブミンと比較してその有効性とコスト効率の高さから成長を牽引しています。プラズマエキスパンダ製造および製剤化における技術の進歩により、安全性と有効性が向上し、医療従事者にとっての入手しやすさと信頼性が高まっています。高度医療技術へのシフトや、世界の重症患者管理への関心の高まりも、救急や集中治療の現場で重要な役割を果たす血漿エキスパンダーへの投資を後押ししています。より安全で効果的な治療オプションへの需要がこの分野の技術革新を促し、新しい製剤が副作用や安全性プロファイルに関する課題に対処しています。

しかし、同市場は、その成長に影響を及ぼす可能性のあるいくつかの課題に直面しています。主な懸念は、特定の合成血漿増量剤、特に腎臓障害につながる例もあるヒドロキシエチルスターチ（HES）の潜在的な副作用です。新製品の承認や複雑な臨床試験に関する規制上の課題は、新しい治療法のイントロダクションを遅らせる可能性があります。血漿由来製剤は高価であるため、リソースの乏しい環境では入手が制限され、ヒトアルブミンなどのヒト由来製剤に依存すると、供給不足、倫理的配慮、病原体トランスミッションのリスクなどの懸念が生じる。これらの課題に対処するため、市場はより安全で効果的な代替品の開発に注力するとともに、世界的に高まるプラズマエキスパンダ治療への需要に対応するため、アクセシビリティの向上に努めなければならないです。

主な市場促進要因

技術の進歩

主な市場課題

コスト抑制

主要市場動向

輸血よりも血漿エキスパンダーへのシフト：

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のプラズマエキスパンダ市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（デキストラン、ヒドロキシエチルスターチ、ヒトアルブミン、PEG化アルブミン、ポリビニルピロリドン（PVP）、ゼラチン）
  • エンドユーザー別（オンライン薬局、小売薬局、病院薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のプラズマエキスパンダ市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のプラズマエキスパンダ市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のプラズマエキスパンダ市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のプラズマエキスパンダ市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのプラズマエキスパンダ市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のプラズマエキスパンダ市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Baxter International Inc
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Plasma Expander Market was valued at USD 7.32 billion in 2024 and is projected to grow to USD 15.03 billion by 2030, with a CAGR of 12.71%. This market is poised for significant expansion, driven by increasing healthcare demands for volume replacement in critical conditions such as trauma, surgery, burns, and shock. Plasma expanders, vital intravenous solutions, help to restore blood volume and are essential in treating severe dehydration and blood loss. Additionally, the rising prevalence of chronic conditions like heart failure, liver disease, and kidney disorders is further accelerating the demand for these products, as they play a crucial role in managing fluid balance and maintaining cardiovascular health for critically ill patients. The growing frequency of surgeries and intensive medical procedures is also fueling market growth.

Several factors are contributing to the rapid progress of the plasma expander market. The increasing adoption of synthetic plasma expanders, such as Hydroxyethyl Starch (HES) and other synthetic colloids, is driving growth due to their effectiveness and cost-efficiency compared to human albumin. Technological advancements in plasma expander manufacturing and formulation are improving their safety and efficacy, enhancing their accessibility and reliability for healthcare providers. The shift toward advanced medical technologies and a heightened focus on critical care management globally is also encouraging investments in plasma expanders, which are crucial in emergency and intensive care settings. Demand for safer and more effective treatment options is prompting innovation in this field, with new formulations addressing challenges related to side effects and safety profiles.

However, the market faces several challenges that may affect its growth. A key concern is the potential side effects of certain synthetic plasma expanders, particularly Hydroxyethyl Starch (HES), which has been linked to kidney damage in some instances. Regulatory challenges related to the approval of new products and complex clinical trials can delay the introduction of new therapies. The high cost of plasma-derived products limits accessibility in low-resource settings, and reliance on human-derived products, such as human albumin, raises concerns about supply shortages, ethical considerations, and the risk of pathogen transmission. To address these challenges, the market must focus on developing safer and more effective alternatives while improving accessibility to meet the growing demand for plasma expander treatments globally.

Key Market Drivers

Technological Advancements:

Researchers are actively working on developing new formulations of plasma expanders to improve volume-expanding properties while reducing side effects like coagulation disturbances and kidney injury. Advances are also being made in the creation of synthetic plasma expanders that do not rely on human or animal plasma, reducing the risk of infections and immunological reactions. The development of biodegradable plasma expanders, which break down naturally in the body over time, is also underway. Additionally, nanotechnology is being used to enhance the properties of plasma expanders by improving drug delivery, circulation time, and tissue targeting. Technological innovations have led to improved safety profiles, longer shelf life, and more accurate real-time monitoring of patient responses to plasma expanders. In India, for example, the Department of Science and Technology (DST) and the Central Institute of Petrochemicals Engineering & Technology (CIPET) have been pivotal in promoting research and development in this area, further contributing to the advancement of plasma expanders.

Key Market Challenges

Cost Containment:

Healthcare systems globally face budget constraints, leading to cost-containment measures that may impact the purchasing of plasma expanders. The plasma expander market is highly competitive, with multiple manufacturers offering a range of products, which may result in price pressure and reduced profit margins. Additionally, reimbursement policies from government and private insurers can impact the financial viability of plasma expander products, and economic downturns can shift preferences toward cost-effective alternatives. The high costs associated with research, development, and regulatory compliance also complicate the market dynamics, requiring manufacturers to balance affordability with profitability. Efficient supply chain management is essential for reducing costs related to production, distribution, and storage.

Key Market Trends

Shift Toward Plasma Expanders Over Blood Transfusions:

The preference for plasma expanders over blood transfusions is a major driver for market growth. While blood transfusions have traditionally been used to treat significant blood loss, they carry risks such as immunological reactions, infections, blood type mismatches, and allergic responses. Plasma expanders, by mimicking human plasma, offer a safer alternative as they do not carry the same risks of transfusion reactions and infections. They are easier to store, have a longer shelf life, and are more cost-effective than blood transfusions, which involve high costs for blood collection, screening, and storage. As healthcare systems focus on improving trauma care efficiency, plasma expanders are increasingly becoming the preferred method for volume restoration in critical patients, particularly in emergency settings and remote areas with limited access to blood banks.

Key Market Players

• Baxter International Inc.
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

Report Scope:

This report segments the Global Plasma Expander Market by product type, end-user, and region, highlighting industry trends and market dynamics.

Product Type Segmentation:

• Dextran
• Hydroxyethyl Starch
• Human Albumin
• PEGylated Albumin
• Polyvinylpyrrolidone (PVP)
• Gelatin

End-User Segmentation:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Regional Segmentation:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East & Africa

Competitive Landscape:

Detailed profiles of key market players are included in the report.

Available Customizations:

TechSci Research offers customization options for the Global Plasma Expander Market report, including additional market player analysis and other specific insights tailored to company needs.

Additional company analysis and profiling (up to five additional market players).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Expander Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Dextran, Hydroxyethyl Starch, Human Albumin, PEGylated Albumin, Polyvinylpyrrolidone (PVP), Gelatin)
  • 5.2.2. By End User (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Plasma Expander Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Plasma Expander Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. India Plasma Expander Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Australia Plasma Expander Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Japan Plasma Expander Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By End User
  • 6.3.5. South Korea Plasma Expander Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By End User

7. Europe Plasma Expander Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Plasma Expander Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Plasma Expander Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Spain Plasma Expander Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Plasma Expander Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. United Kingdom Plasma Expander Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. North America Plasma Expander Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Plasma Expander Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Mexico Plasma Expander Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Canada Plasma Expander Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User

9. South America Plasma Expander Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Plasma Expander Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Plasma Expander Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Plasma Expander Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Plasma Expander Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Plasma Expander Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Plasma Expander Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Plasma Expander Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Plasma Expander Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Baxter International Inc
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Fresenius SE & Co. KGaA
• 16.3. CSL Limited
• 16.4. Grifols, S.A.
• 16.5. B. Braun Melsungen AG
• 16.6. Hikma Pharmaceuticals PLC
• 16.7. Octapharma AG
• 16.8. Kedrion S.p.A.
• 16.9. Shanghai RAAS Blood Products Co., Ltd.
• 16.10.Terumo Corporation

17. Strategic Recommendations

18. About Us & Disclaimer